AVTR Should I Buy

Bernstein resumed coverage of Avantor with a Market Perform rating and $10.50 price target following a return from maternity leave. \"Many things\" are going right for the life science tools and diagnostics sector, the analyst tells investors in a research note. The firm says new drug approvals, trial starts, and funding are all better in the last 12 months versus the 12 months prior. Bernstein believes funding will start translating into customer spend while re-shoring will drive incremental investment at a time when AI-driven demand for semiconductor-related tools will continue to grow.